Abstract
Immune checkpoint inhibitors revolutionized the treatment of non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies. PD-L1 assessment and tumor mutational burden (TMB) are available tools to optimize use of checkpoint inhibitors but novel tools are needed. Exome sequencing could generate many variables but their role in identifying predictors of response is unknown. We performed somatic and constitutional exome analyses for 77 patients with NSCLC treated with nivolumab. We studied: one-tumor-related characteristics: aneuploidy, CNA clonality, mutational signatures, TMB, mutations in WNT, AKT, MAPK, and DNA repair pathways, and two-immunologic characteristics: number of intratumoral TCR clones, HLA types, and number of neoantigens; and six clinical parameters. A high TMB per Mb, a high number of neoantigens, mutational signatures 1A and 1B, mutations in DNA repair pathways, and a low number of TCR clones are associated with greater PFS. Using a LASSO method, we established an exome-based model with nine exome parameters that could discriminate patients with good or poor PFS (P < 0.0001) and overall survival (P = 0.002). This model shows better ability to predict outcomes compar...Continue Reading
References
Dec 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chengwen LiuPatrick Hwu
Dec 20, 2012·PloS One·Jan BudcziesCarsten Denkert
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Nov 18, 2014·Statistics in Medicine·Le KangBrandon D Gallas
Nov 28, 2014·Nature·Paul C TumehAntoni Ribas
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Feb 24, 2015·The Lancet Oncology·Naiyer A RizviSuresh S Ramalingam
Mar 15, 2015·Science·Naiyer A RizviTimothy A Chan
Apr 9, 2015·Genome Biology·Mihaela AngelovaZlatko Trajanoski
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Dec 10, 2015·Cancer Discovery·Weiyi PengPatrick Hwu
Dec 30, 2015·Lancet·Roy S HerbstEdward B Garon
Jan 23, 2016·Expert Opinion on Biological Therapy·Sung Hee LimMyung-Ju Ahn
Mar 14, 2016·Lancet·Louis FehrenbacherUNKNOWN POPLAR Study Group
Aug 4, 2016·Current Oncology Reports·Raffaele CalifanoAntonio Rossi
Aug 18, 2016·Journal for Immunotherapy of Cancer·Claud Grigg, Naiyer A Rizvi
Dec 17, 2016·Lancet·Achim RittmeyerUNKNOWN OAK Study Group
Mar 24, 2017·Biomarker Research·Laurence P Diggs, Eddy C Hsueh
Apr 27, 2017·The New England Journal of Medicine·Mariam Jamal-HanjaniUNKNOWN TRACERx Consortium
May 30, 2017·PLoS Medicine·Alexandra SnyderDean F Bajorin
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Jan 6, 2018·Science·Diana MiaoEliezer M Van Allen
Jan 18, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hira RizviMatthew D Hellmann
Apr 17, 2018·Cancer Cell·Matthew D HellmannJedd D Wolchok
Citations
May 29, 2019·Cell Biology International·Masoud NajafiKeywan Mortezaee
May 23, 2019·Molecular Cytogenetics·Andréa E TijhuisSarah E McClelland
Aug 18, 2020·Current Oncology Reports·Camille TravertPascale Tomasini
Jan 22, 2020·Scientific Reports·Sohyun HwangHee Jung An
Oct 6, 2020·Scandinavian Journal of Immunology·Andreas HallqvistSukanya Raghavan
Oct 29, 2020·International Journal of Immunogenetics·Milena Ivanova, Velizar Shivarov
Nov 3, 2020·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Arthur KrauseLukas Bubendorf
Nov 13, 2020·Oncoimmunology·Soleine MedjebarFrançois Ghiringhelli
Oct 28, 2020·Genome Medicine·Riyue BaoJason J Luke
Feb 9, 2021·World Journal of Clinical Cases·Min ChenHai-Tao Wu
Nov 12, 2020·Life·Chiao-En WuChun-Nan Yeh
Feb 26, 2021·Journal of Cellular and Molecular Medicine·Xiaozhu ZengYuxi Zhu
Feb 26, 2021·Seminars in Cancer Biology·Yin WuCharles Swanton
Apr 13, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jean-David FumetFrancois Ghiringhelli
May 1, 2021·Frontiers in Immunology·Jiehan JiangKui Xiao
Jun 1, 2021·Cellular Oncology (Dordrecht)·Mathew LozinskiPaul A Tooney
Aug 12, 2021·Cancer Immunology, Immunotherapy : CII·Mizuki KobayashiMasaki Shiota
Aug 10, 2021·Frontiers in Immunology·Shuyue WangTengfei Liu
Jun 12, 2020·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lynette M ShollJohn W Longshore
Dec 12, 2021·Journal for Immunotherapy of Cancer·Manish A ShahDaniel V T Cantenacci